Online inquiry

IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5844MR)

This product GTTS-WQ5844MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5844MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10299MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ10666MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ3507MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ7501MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ12770MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ1956MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ7058MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ604MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW